Joined: 2/17/2019
Posts: 379
|
Clinical trial announced for Intra Nasal light therapy in the US and Canada
https://www.globenewswire.com/news-release/2019/06/04/1863765/0/en/Vielight-Commences-Pivotal-Clinical-Trial-for-Alzheimer-s-Disease-based-on-Transcranial-Photobiomodulation.html
Vielight Commences Pivotal Clinical Trial for Alzheimer’s Disease based on Transcranial Photobiomodulation.
Tell you doctor if you are interested in this clinical trial, its reference number is NCT03484143,
and Please HELP me get the word out to people with this disease, their caregivers,
the results from their 5 person research trial were all positive, it actually reduced symptoms, improved quality of life for patient, and subsequently, for the caregiver, its a wearable helmet and takes 20 minutes a day. It will run in Toronto, and in.. uh Essex County.
If your relative cannot travel to the site for the check ins once every 3 weeks, it is possible to buy the darn thing outright from their site, (although, honestly, its a Canadian company, they should have prices in Canadian dollars, but at par to the US prices, no?)
- there are also other devices that flash light and sound at 40hz, its called photo modulation or neuro modulation and range in price from 39 USD to 599, and have already have noted 'anecdotal' symptom improvement from the non-medical alzheimer's community.
- Adafruit has a DIY kit, DAVID devices seems like a pretty big company, their most expensive device is around 600, again USD, and there is an option where you can opt to have GAMMA waves added to its programming.
- ALZ life is in clinical trials
- There are some Light and Sound Machine companies that sell software you can use on a computer
If interested have a look at my other posts for more info on the 40hz sound and light that is cheaper, and not in a clinical trial.
* * * *
Email Print Friendly Share
June 04, 2019 06:00 ET | Source: Vielight Inc.photo-release
The Vielight Neuro RX Gamma device in use.
Toronto, Canada, June 04, 2019 (GLOBE NEWSWIRE)
--
Vielight Inc. of Toronto, a leader in brain photobiomodulation (PBM) technology, announces that the primary site for its pivotal clinical trial, St. Michael’s Hospital, in Toronto, has been activated.
The trial will be a randomized, placebo-controlled study involving 228 subjects with moderate to severe cognitive impairment due to Alzheimer’s Disease.
This pivotal trial will be conducted across North America. St. Michael’s Hospital is the first among the eight sites that will carry out the study. The protocol of the study has been reviewed by the U.S. Food and Drug Administration (FDA) and Health Canada.
The device in investigation, called the “Vielight Neuro RX Gamma”, is based on Vielight’s proprietary PBM technology which directs near infrared light, pulsing at the gamma rate of 40 Hz, to selected regions of the brain.
The procedure is non-invasive, and the device has been designed to be suitable for home-use. Subject to regulatory clearance, the device will be indicated for Alzheimer patients with moderate to severe impairment, the group that demands the most care and has the largest economic burden.
This clinical trial is timely against the backdrop of many unsuccessful attempts by pharmaceutical and device companies to demonstrate acceptable efficacy and safety to address the disease.
Currently, no other modality is in a clinical trial that is expected to demonstrate clinical outcomes within the time anticipated for the Vielight study to be completed.
Recently published studies have shed more light on the potential of the Neuro RX Gamma to modify the pathology of Alzheimer’s Disease.
These studies presented findings in clinical assessments and functional magnetic resonance imaging (fMRI), warranting the move forward with the large pivotal clinical trial.
Recruitment for the study will begin shortly. The trial will be independently managed by the Applied Health Research Centre (AHRC), a methodology center affiliated with St. Michael’s Hospital.
Further information and contact details for participation enquiries can be found at https://clinicaltrials.gov/ct2/show/NCT03484143.
|
Joined: 2/17/2019
Posts: 379
|
|